WHO seeks additional clarification from Bharat Biotech, decision on November 3
By Administrator_ India
The technical advisory group of the World Health Organisation on October 26 sought “additional clarifications” from Bharat Biotech to conduct a final “risk-benefit assessment” for Emergency Use Listing of its COVID-19 vaccine.
The statement came hours after WHO official Dr. Margaret Harris had said that a recommendation was expected within the next 24 hours.
The technical advisory group will now meet on November 3 for a final assessment.
“The WHO independent TAG met today & asked for additional clarifications from the manufacturer BharatBiotech to conduct a final EUL risk-benefit assessment for global use of Covaxin. It will reconvene for the final assessment on Wednesday, 3 November if data is received soon,” WHO Chief Scientist Soumya Swaminathan tweeted.
Hyderabad-based Bharat Biotech, which has developed Covaxin, had submitted EOI (Expression of Interest) to the WHO on April 19 for the vaccine’s Emergency Use Listing (EUL).
Earlier in the day, Harris had said that on Covaxin, the technical advisory group that reviews all the data for a potential emergency use listing was reviewing that data.
